Phase 2/3, randomized, double-blind, placebo- and active comparator-controlled, parallel, multicenter study to determine safety and efficacy of metaglidasen in treatment of type 2 diabetes suboptimally controlled on insulin

Trial Profile

Phase 2/3, randomized, double-blind, placebo- and active comparator-controlled, parallel, multicenter study to determine safety and efficacy of metaglidasen in treatment of type 2 diabetes suboptimally controlled on insulin

Completed
Phase of Trial: Phase II/III

Latest Information Update: 12 May 2015

At a glance

  • Drugs Arhalofenate (Primary) ; Pioglitazone
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors CymaBay Therapeutics; Metabolex
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2011 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
    • 26 Mar 2008 Status changed from in progress to completed, as reported in a Metabolex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top